Macclesfield, United Kingdom

Zbigniew Stanley Matusiak

USPTO Granted Patents = 14 


 

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 141(Granted Patents)


Location History:

  • Macclesfield Cheshire, GB (2004 - 2006)
  • Cheshire, GB (2006)
  • Macclesfield, GB (2007 - 2023)

Company Filing History:


Years Active: 2004-2025

Loading Chart...
Loading Chart...
Loading Chart...
14 patents (USPTO):Explore Patents

Title: **Innovator Zbigniew Stanley Matusiak: Pioneering Advances in Cancer Treatment**

Introduction

Zbigniew Stanley Matusiak, an accomplished inventor based in Macclesfield, GB, has made significant contributions to the field of medicinal chemistry. With an impressive portfolio of 14 patents, Matusiak has been at the forefront of innovations targeted at enhancing therapeutic interventions, particularly in the fight against cancer.

Latest Patents

Among his latest innovations, Matusiak developed a novel group of compounds, designated as Protein Kinase B inhibitors. The invention centers around specific compounds described by a distinct chemical formula, which are anticipated to be effective in treating or preventing various diseases mediated through Protein Kinase B (PKB), including cancer. This innovative work also encompasses the creation of pharmaceutical compositions containing these compounds, methods for treating PKB-mediated diseases with these compounds, and protocols for their preparation, showcasing Matusiak’s deep commitment to advancing health care solutions.

Career Highlights

Zbigniew Stanley Matusiak is associated with AstraZeneca, a global leader in biopharmaceuticals focused on the discovery and development of innovative medicines. His work at the company highlights his role in pushing the boundaries of medical science, particularly in oncology. Matusiak’s contributions are rooted in thorough research and an unwavering commitment to improving patient outcomes through innovative therapeutic strategies.

Collaborations

Throughout his career, Matusiak has collaborated with notable colleagues, including Richard William Arthur Luke and Paul David Johnson. These partnerships have nurtured a dynamic environment committed to research excellence and have driven forward various projects that align with the collective goal of enhancing treatment modalities in medical science.

Conclusion

In summary, Zbigniew Stanley Matusiak stands out as a key figure in the realm of pharmaceutical innovation. His extensive work, particularly in the development of Protein Kinase B inhibitors, promises to contribute significantly to the treatment and management of cancer. As Matusiak continues to forge ahead with his research efforts, the potential impact of his inventions on healthcare remains promising and noteworthy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…